Kneat.com (KSI) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
14 May, 2026Executive summary
Revenue grew 22% year-over-year to $18.0 million in Q1 2026, with Annual Recurring Revenue (ARR) up 20% to $76.4 million, reflecting strong customer expansion and alignment with strategic goals.
Gross profit increased 28% to $14.0 million, with gross margin improving to 78% from 74%.
Two significant customer expansions expected in Q1 closed in early April, and multiple new contracts were signed with major biopharma and pharmaceutical manufacturers.
Customers are increasingly adopting digital validation, with 87% still using paper-based processes and 80% reporting rising validation workloads.
The company is evolving from document-centric to data-centric workflows, enhancing its value proposition and customer alignment.
Financial highlights
Q1 revenue reached $18.0 million, up from $14.7 million in Q1 2025, a 22% increase year-over-year.
ARR grew to $76.4 million, up 20% year-over-year, with FX providing a CAD 900,000 tailwind sequentially but a CAD 950,000 headwind year-over-year.
Gross margin expanded to 78% due to improved cloud hosting economics and higher services revenue.
Net loss of $3.9 million in Q1 2026, compared to net income of $2.1 million in Q1 2025.
Adjusted EBITDA rose to $2.7 million from $2.3 million year-over-year.
Outlook and guidance
Management expects incremental ARR to remain back-end loaded, consistent with historical patterns.
Professional services revenue is expected to be higher in 2026 than in 2025, with gross margins stable at current levels.
The company remains committed to achieving cash flow positivity for the full year 2026.
Management expresses confidence in continued growth, citing strong sales pipeline and industry digitalization trends.
Customer feedback and industry studies indicate sustained demand for digital validation solutions.
Latest events from Kneat.com
- ARR hits CAD 74M, AI features expand, and profitability is targeted for 2026.KSI
Emerging Growth Conference 911 Apr 2026 - Software revenue up 33% in 2025; ARR at $74.1m; targeting cash flow breakeven in 2026.KSI
Q4 202526 Feb 2026 - SaaS validation platform achieves 138% net revenue retention and targets $2B+ ARR in life sciences.KSI
Small-Cap Growth Virtual Investor Conference 20243 Feb 2026 - ARR rose 60% and gross margin reached 74% in Q2 2024, with strong SaaS and partner growth.KSI
Q2 20242 Feb 2026 - Aggressive drilling at Coyote begins soon, targeting high-grade uranium in a fully funded campaign.KSI
Emerging Growth Conference 8921 Jan 2026 - Digitized validation leader achieves rapid ARR growth and major efficiency gains for life sciences.KSI
Investor presentation21 Jan 2026 - Record Q3 revenue, ARR, and margin growth, with new global contracts and strong outlook.KSI
Q3 202415 Jan 2026 - High-growth validation software leader drives digital transformation in life sciences.KSI
Planet MicroCap Showcase: VEGAS 202527 Dec 2025 - Record SaaS-driven growth, high margins, and strong cash position support 2025 momentum.KSI
Q4 202416 Dec 2025